Blair William & CO Affimed N.V. Transaction History

Blair William & CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $18,450 - $28,250	-5,000 Reduced 30.3%	11,500 $50,000
Q1 2021 May 13, 2021	SELL	$5.12 - $8.48 $17,920 - $29,680	-3,500 Reduced 17.5%	16,500 $131,000
Q4 2020 Feb 09, 2021	BUY	$3.16 - $7.03 $63,200 - $140,600	20,000 New	20,000 $116,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.